Skip to main content
Elsevier

Hypoxia-induced Tumor Heterogeneity and Immune Evasion

Clinical Interventions

  • 1st Edition - February 1, 2027
  • Latest edition
  • Editors: Benjamin Bonavida, Salem Chouaib
  • Language: English

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune… Read more

Back to School

Start strong. Study with purpose.

Save up to 25% on trusted learning resources

Shop now

Description

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. The volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. It is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance.

By bringing together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes, this resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.

Key features

  • Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancer
  • Presents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamics
  • Equips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes

Readership

Researchers in oncology, immunology, and molecular biology.

Table of contents

Part I: Introduction and Foundation

1. Overview of Tumor Heterogeneity

2. Molecular Basis of Hypoxia

3. Tumor Heterogeneity

4. Environmental Carcinogenesis and Hypoxia

Part II: Hypoxia as a Driver of Tumor Heterogeneity

5. Hypoxia-Induced Clonal Evolution

6. Metabolic Reprogramming by Hypoxia

7. Hypoxia-Driven Angiogenesis

8. Epigenetics and Hypoxia

9. Glycobiology, Vascular Biology and Hypoxia

Part III: Immune Evasion Under Hypoxic Conditions

10. Immune Landscape of Hypoxic Tumors

11. Molecular Mechanisms of Immune Evasion

12. Cross-talk Between Hypoxia and Immunotherapy Resistance

Part IV: Translation and Clinical Perspectives

13. Diagnostic and Imaging

14. Hypoxia-Targeted Therapies

15. Overcoming Immune Evasion Clinically

16. Clinical Strategies to Overcome Immune Evasion

Part V: Future Directions and Challenges

17. Emerging Technologies

18. Personalized Medicine and Precision Oncology

19. Ethical and Regulatory Considerations

Part VI: Conclusions

20. Overall Concluding Remarks

21. References

Product details

  • Edition: 1
  • Latest edition
  • Published: February 1, 2027
  • Language: English

About the editors

BB

Benjamin Bonavida

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).

Affiliations and expertise
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA

SC

Salem Chouaib

Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.
Affiliations and expertise
Research Director, Gustave Roussy Cancer Center, Villejuif, France